During a satellite symposium at ESC Heart Failure 2017 in Paris, organised by PACE-CME, the increased CV risk in diabetic patients with HF was discussed, and which novel treatments can be considered in these patients.
ESC HF 2017 Diabetes worsens risk associated with various CV conditions. Prof. David Fitchett considers the therapeutic options to minimise this CV risk and the increasing role of cardiologists in current optimal management of CV patients with diabetes.
ESC HF 2017 The HeartLogic system combines parameters including heart sound, respiratory rate and patient activity, to identify HF patients at risk of developing decompensation. Prof. Cowie discusses what remains to be done to advance the field.
ESC HF 2017 At the ESC HF congress in Paris, professor Voors shares the disappointing results of the RELAX-AHF, in which treatment with serelaxin in acute HF did not result in improvement in mortality and worsening HF
Heart failure is the most disabling and deadly complication of diabetes. Prof. John McMurray summarizes the results with various new treatments for diabetes that may affect the risk of developing heart failure.
ESC HF 2017 Data at 52 weeks of the CHART-1 study showed changes in LV measures suggestive of a beneficial remodelling effect. The number of injections influenced the changes.
ESC HF 2017 Milton Packer and Alexandre Mebazaa discussed whether vasodilators have a role in management of Acute HF and why or why not, and what additional options are needed.
ESC HF 2017 Based on heart sounds, respiration rate, and volume, thoracic impedance, night heart rate, and daily activity HeartLogic predicts the risk of an HF event independent of baseline variables.
ESC HF 2017 Impression of this new session type, in which John McMurray and Mariell Jessup debated why or why not ARNI should be considered first-line therapy in patients with heart failure.
ESC HF 2017 Pooled individual patient data reveal that slowing heart rate with a betablocker lowers mortality in sinus rhythm, while in AF patients baseline or attained heart rate does not affect mortality.
ESC HF 2017 In EDIFY, treatment with ivabradine for 8 months reduced heart rate, but did not improve E/e’, exercise capacity or NT-proBNP levels in patients with HFpEF.
ESC HF 2017 In EMPA-REG OUTCOME, treatment with empagliflozin first lowered and then stabilised eGFR, while placebo patients showed a decline in the chronic treatment phase.